Scarica l'app Stockscreener
0.95
0.02%
-0.0002
Dopo l'orario di chiusura:
.95
Precedente Chiudi:
$0.9502
Aprire:
$0.9521
Volume 24 ore:
4,811
Relative Volume:
0.02
Capitalizzazione di mercato:
$4.83M
Reddito:
-
Utile/perdita netta:
$-21.13M
Rapporto P/E:
-0.1983
EPS:
-4.79
Flusso di cassa netto:
$-16.95M
1 W Prestazione:
-5.00%
1M Prestazione:
+7.94%
6M Prestazione:
+59.13%
1 anno Prestazione:
+463.46%
Intervallo 1D:
$0.95
$0.98
Intervallo di 1 settimana:
$0.9115
$1.04
Portata 52W:
$0.09
$4.49
Matinas Biopharma Holdings Inc Stock (MTNB) Company Profile
Nome
Matinas Biopharma Holdings Inc
Settore
Industria
Telefono
908-443-1860
Indirizzo
1545 Route 206 South, Suite 302, Bedminster, NJ
Confronta MTNB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MTNB
Matinas Biopharma Holdings Inc
|
0.95 | 4.83M | 0 | -21.13M | -16.95M | -4.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
476.95 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.39 | 60.56B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.64 | 42.41B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
575.42 | 34.96B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.83 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Matinas Biopharma Holdings Inc Stock (MTNB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-05-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2020-08-26 | Ripresa | Piper Sandler | Overweight |
| 2020-01-27 | Iniziato | Piper Sandler | Overweight |
| 2020-01-24 | Iniziato | SunTrust | Buy |
| 2020-01-23 | Iniziato | SunTrust | Buy |
| 2020-01-09 | Iniziato | Aegis Capital | Buy |
| 2019-06-26 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Matinas Biopharma Holdings Inc Borsa (MTNB) Ultime notizie
Is Matinas BioPharma Holdings Inc. a good long term investmentBreakthrough profit margins - Autocar Professional
What analysts say about HASI stockFree Investment Timing Strategies - jammulinksnews.com
How Matinas BioPharma Holdings Inc. stock performs during market volatilitySmart Return Focused Trading - Newser
Matinas BioPharma Holdings Inc. Stock Analysis and ForecastBreakout profit opportunities - jammulinksnews.com
What drives Matinas BioPharma Holdings Inc. stock priceFree Stock Market Mentorship - jammulinksnews.com
What analysts say about Matinas BioPharma Holdings Inc. stockExceptional portfolio growth - Autocar Professional
Is Renovaro Inc. a good long term investmentSuperior capital gains - jammulinksnews.com
What makes Matinas BioPharma Holdings Inc. stock price move sharplyShort Squeeze Radar - beatles.ru
What analysts say about WRAP stockOutstanding capital returns - jammulinksnews.com
Why Matinas BioPharma Holdings Inc. stock attracts strong analyst attentionQuick Profit Idea Stream - Newser
Why Hayward Holdings Inc. stock attracts strong analyst attentionFree Stock Movement Tracking - Newser
Aspergillosis Pipeline 2025: FDA Updates, Therapy - openPR.com
Diversification Wins: Global ETFs Shine in First Half of 2025 - The Globe and Mail
Matinas BioPharma Approves 2025 Equity Incentive Plan - TipRanks
MTNB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Pre-market Movers: HCTI, KLTO, INTS, HSDT... - RTTNews
Kalkine Matinas BioPharma Surges Amid NYSE Composite Market Momentum - Kalkine Media
Matinas Biopharma (NYSE:MTNB) Trading 5.7% Higher – Here’s Why - Defense World
Matinas Biopharma (NYSE:MTNB) versus Marker Therapeutics (NASDAQ:MRKR) Head to Head Review - Defense World
Matinas BioPharma amends bylaws, updates on officer agreements By Investing.com - Investing.com Canada
Matinas BioPharma Amends Bylaws and Sets Annual Meeting - TipRanks
Matinas BioPharma amends bylaws, updates on officer agreements - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Matinas Biopharma (NYSE:MTNB) Shares Down 2.6% – Here’s What Happened - Defense World
MTNB stock touches 52-week low at $0.48 amid sharp annual decline - Investing.com Australia
MTNB stock touches 52-week low at $0.48 amid sharp annual decline By Investing.com - Investing.com South Africa
Matinas BioPharma secures shareholder nods on key proposals By Investing.com - Investing.com Australia
Matinas Biopharma Holdings Inc Azioni (MTNB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.91%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):